Vyndamax FDA Approval History
FDA Approved: Yes (First approved May 3, 2019)
Brand name: Vyndamax
Generic name: tafamidis
Dosage form: Capsules
Company: Pfizer Inc.
Treatment for: Cardiomyopathy of Transthyretin-Mediated Amyloidosis
Vyndamax (tafamidis) is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis.
Development Timeline for Vyndamax
|May 6, 2019||FDA Approves New Treatments Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) for Heart Disease Caused by Transthyretin Mediated Amyloidosis|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.